217 related articles for article (PubMed ID: 24554919)
1. Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis.
Goel D
J Pharmacol Pharmacother; 2014 Jan; 5(1):76-8. PubMed ID: 24554919
[TBL] [Abstract][Full Text] [Related]
2. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
3. Extensively drug-resistant tuberculosis: epidemiology and management.
Matteelli A; Roggi A; Carvalho AC
Clin Epidemiol; 2014; 6():111-8. PubMed ID: 24729727
[TBL] [Abstract][Full Text] [Related]
4. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
Centers for Disease Control and Prevention (CDC)
MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
[TBL] [Abstract][Full Text] [Related]
5. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.
Pecora F; Dal Canto G; Veronese P; Esposito S
Microorganisms; 2021 May; 9(5):. PubMed ID: 34067732
[TBL] [Abstract][Full Text] [Related]
7. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?
Field SK
Ther Adv Chronic Dis; 2015 Jul; 6(4):170-84. PubMed ID: 26137207
[TBL] [Abstract][Full Text] [Related]
8. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
Kunkel A; Cobelens FG; Cohen T
PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274
[TBL] [Abstract][Full Text] [Related]
9. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
[TBL] [Abstract][Full Text] [Related]
10. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.
Dheda K; Chang KC; Guglielmetti L; Furin J; Schaaf HS; Chesov D; Esmail A; Lange C
Clin Microbiol Infect; 2017 Mar; 23(3):131-140. PubMed ID: 27756712
[TBL] [Abstract][Full Text] [Related]
11. Multidrug and extensively drug-resistant tuberculosis.
Maitre T; Aubry A; Jarlier V; Robert J; Veziris N;
Med Mal Infect; 2017 Feb; 47(1):3-10. PubMed ID: 27637852
[TBL] [Abstract][Full Text] [Related]
12. Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis.
Lakshmanan M; Xavier AS
J Young Pharm; 2013 Dec; 5(4):112-5. PubMed ID: 24563587
[TBL] [Abstract][Full Text] [Related]
13. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
[TBL] [Abstract][Full Text] [Related]
14. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.
D'Ambrosio L; Centis R; Tiberi S; Tadolini M; Dalcolmo M; Rendon A; Esposito S; Migliori GB
J Thorac Dis; 2017 Jul; 9(7):2093-2101. PubMed ID: 28840010
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation.
Starshinova A; Dovgalyk I; Belyaeva E; Glushkova A; Osipov N; Kudlay D
Antibiotics (Basel); 2022 Nov; 11(11):. PubMed ID: 36421267
[TBL] [Abstract][Full Text] [Related]
16. New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline.
Leibert E; Danckers M; Rom WN
Ther Clin Risk Manag; 2014; 10():597-602. PubMed ID: 25114537
[TBL] [Abstract][Full Text] [Related]
17. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
18. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
Kim JH; Kwon OJ; Kim YS; Park MS; Hwang S; Shim TS
Respir Investig; 2020 Jan; 58(1):45-51. PubMed ID: 31635903
[TBL] [Abstract][Full Text] [Related]
19. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
Chahine EB; Karaoui LR; Mansour H
Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
